CDT Equity signs evaluation deal with Manoira for animal health uses of two compounds

CDT Equity Inc. (Nasdaq: CDT) said on October 27, 2026 that it had signed an evaluation agreement with Manoira Corporation, dated October 22, 2026, covering two of CDT's clinical-stage compounds. The deal lets Manoira, a specialty animal health company, study whether CDT's assets AZD1656, including certain proprietary cocrystal derivatives, and AZD5904 could enhance products Manoira plans to bring to market.¹

Manoira expects to launch its first set of animal health products in the first quarter of 2027, using licensed cannabinoid cocrystal and solid-form technology.¹ The company said it is currently manufacturing and testing those products ahead of launch.¹

Under the agreement, CDT will give Manoira access to materials from AZD1656, including certain cocrystal derivatives, and AZD5904.¹ Manoira will then check whether adding either compound makes its products work better, safer, or more commercially viable, and if that testing succeeds, the two companies plan to discuss licensing and commercial terms for any resulting products once they launch.

The 8-K filing also disclosed related share issuances. CDT issued 1,347,616 shares of common stock at $0.1447 per share to settle a $195,000 payment owed to Manoira under the agreement.¹ The filing noted a conflict-related disclosure: Dr. Andrew Regan, CDT's former Chief Executive Officer and a former board member, owns more than five percent of CDT's outstanding common stock and is the sole director of Manoira, though he will not receive any consideration from the transaction.¹

Separately, the filing disclosed other recent stock issuances, including 397,374 shares to a service provider for consulting services¹ and 499,616 shares to Dr. Regan in lieu of $65,000 in severance tied to his resignation as CEO.¹